IL138979A0 - Use of cannabinoids as anti-inflammatory agents - Google Patents

Use of cannabinoids as anti-inflammatory agents

Info

Publication number
IL138979A0
IL138979A0 IL13897999A IL13897999A IL138979A0 IL 138979 A0 IL138979 A0 IL 138979A0 IL 13897999 A IL13897999 A IL 13897999A IL 13897999 A IL13897999 A IL 13897999A IL 138979 A0 IL138979 A0 IL 138979A0
Authority
IL
Israel
Prior art keywords
cannabinoids
inflammatory agents
inflammatory diseases
treating inflammatory
cannabidiol
Prior art date
Application number
IL13897999A
Other languages
English (en)
Original Assignee
Mathilda & Terrence Kennedy In
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mathilda & Terrence Kennedy In, Yissum Res Dev Co filed Critical Mathilda & Terrence Kennedy In
Publication of IL138979A0 publication Critical patent/IL138979A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13897999A 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents IL138979A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
PCT/GB1999/001140 WO1999052524A1 (fr) 1998-04-14 1999-04-14 Utilisation de cannabinoides comme agents anti-inflammatoires

Publications (1)

Publication Number Publication Date
IL138979A0 true IL138979A0 (en) 2001-11-25

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13897999A IL138979A0 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Country Status (12)

Country Link
US (1) US6410588B1 (fr)
EP (1) EP1071417B1 (fr)
JP (1) JP2002511411A (fr)
AT (1) ATE288749T1 (fr)
AU (1) AU757945B2 (fr)
CA (1) CA2328368C (fr)
DE (1) DE69923671T2 (fr)
DK (1) DK1071417T3 (fr)
ES (1) ES2241277T3 (fr)
GB (1) GB9807639D0 (fr)
IL (1) IL138979A0 (fr)
WO (1) WO1999052524A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US6274635B1 (en) 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
SK286421B6 (sk) * 2000-10-31 2008-09-05 Pharma Mar, S. A. Prostriedok kahalalid F, súprava, rekonštituovanýa zriedený roztok s obsahom tohto prostriedku a použitie
EP1206934A1 (fr) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blocage des canaux sodiques par des dérivés phénoliques
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003075917A1 (fr) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Polytherapie destinee a traiter, prevenir ou gerer des troubles proliferatifs et des cancers
ATE533472T1 (de) * 2002-08-14 2011-12-15 Gw Pharma Ltd Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
US20080262079A1 (en) * 2004-08-09 2008-10-23 Bernard Mach Cannabinoid Compositions and Methods of Use Thereof
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2007105210A2 (fr) 2006-03-13 2007-09-20 Hadasit Medical Research Services & Development Limited Utilisations thérapeutiques de composés de cannabidiol
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9956182B2 (en) 2013-05-02 2018-05-01 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
EP3277260B1 (fr) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Extraits végétaux de crassifolium erodium l'her et leurs utilisations
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20180296521A1 (en) * 2015-10-16 2018-10-18 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (fr) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations d'huile d'argan et de cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US20190314297A1 (en) 2016-11-02 2019-10-17 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
CA3055060A1 (fr) 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions et methodes pour le traitement du cancer
AU2017424129B2 (en) * 2017-07-18 2021-12-09 Deyi Pharmarmaceutical Ltd. Application of cannabidiol in treatment of pulmonary hypertension
KR20200054171A (ko) * 2017-08-14 2020-05-19 지네르바 파마슈티컬스, 인코포레이티드 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
WO2020081513A1 (fr) * 2018-10-16 2020-04-23 Systamedic Inc. Nouvelles compositions pour le traitement de maladies inflammatoires
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
CA3128400A1 (fr) * 2019-02-11 2020-08-20 John R. Chancey Procedes de fabrication et d'utilisation de phytocannabinoides complexes avec une proteine, un peptide, un acide amine, un polysaccharide, un disaccharide, un un ormonosaccharide
GB2614634B (en) * 2019-04-30 2023-11-08 Greenway Herbal Products Llc Cannabinoid compositions and methods of using
WO2021011935A1 (fr) * 2019-07-18 2021-01-21 Direct Biologics, Llc Préparations comprenant des cellules souches mésenchymateuses ainsi que des cannabinoïdes et leurs procédés d'utilisation
CA3169702A1 (fr) * 2020-04-02 2021-10-07 Joel Bradley LATHAM Methodes et compositions pour le traitement ou la prevention d'une affection inflammatoire
EP4149448A1 (fr) * 2020-05-11 2023-03-22 ADD Advanced Drug Delivery Technologies, Ltd. Utilisations et formulations de cannabinoïdes
IL298059A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
JP2023553335A (ja) 2020-11-24 2023-12-21 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド カンナビノイド誘導体、及び、炎症、疼痛又は肥満の治療におけるそれらの使用
WO2023283684A1 (fr) * 2021-07-15 2023-01-19 Incannex Healthcare Limited Composition comprenant du cannabidiol et de l'hydroxychloroquine dans une capsule combinée à dose fixe
WO2023156983A1 (fr) 2022-02-21 2023-08-24 Universidade Nova De Lisboa Composés et compositions contre des maladies neurodégénératives
EP4230201A1 (fr) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition pour le traitement de maladies neurodégénératives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
JP2002511411A (ja) 2002-04-16
GB9807639D0 (en) 1998-06-10
AU757945B2 (en) 2003-03-13
DE69923671T2 (de) 2006-03-16
DE69923671D1 (de) 2005-03-17
EP1071417A1 (fr) 2001-01-31
ATE288749T1 (de) 2005-02-15
EP1071417B1 (fr) 2005-02-09
US6410588B1 (en) 2002-06-25
CA2328368C (fr) 2009-03-31
AU3436199A (en) 1999-11-01
ES2241277T3 (es) 2005-10-16
CA2328368A1 (fr) 1999-10-21
DK1071417T3 (da) 2005-06-13
WO1999052524A1 (fr) 1999-10-21

Similar Documents

Publication Publication Date Title
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
BR9910251A (pt) Estimulação hematopoiética
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
AU6178198A (en) Method of treating a tumor
GB9621630D0 (en) Treatment of skin disorders
CA2408541A1 (fr) Traitement contre l'eczema et/ou le psoriasis
BG101126A (en) The use of muramylpeptide compounds
DE69905602T2 (de) Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
NO20012569L (no) Anvendelse av aryl-substituerte syklobutylalkylaminer for behandling av urininkontinens
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
MD916G2 (ro) Unguent pentru tratamentul afecţiunilor dentare
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
UA32281A (uk) Засіб "регенерин" для зовнішнього лікування гнійних ран і трофічних виразок
UA30524A (uk) Мазь для лікування гіперкератозів
UA39009A (uk) Спосіб лікування гіпотиреозу

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired